• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Opium Addiction - Pipeline Review, Q1 2011 - Product Image

Opium Addiction - Pipeline Review, Q1 2011

  • Published: March 2011
  • Region: Global
  • 45 pages
  • Global Markets Direct

Opium Addiction - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Opium Addiction - Pipeline Review, Q1 2011', provides an overview of the Opium Addiction therapeutic pipeline. This report provides information on the therapeutic development for Opium Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Opium Addiction. 'Opium Addiction - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Opium Addiction.
- A review of the Opium Addiction products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opium Addiction Overview
Therapeutics Development
An Overview of Pipeline Products for Opium Addiction
Opium Addiction Therapeutics under Development by Companies
Opium Addiction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Opium Addiction Therapeutics - Products under Development by Companies
Opium Addiction Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Opium Addiction Therapeutics Development
Shionogi & Co., Ltd.
Nanotherapeutics, Inc.
AKELA Pharma Inc.
MediciNova, Inc.
Catalyst Pharmaceutical Partners, Inc.
Orexo AB
Camurus AB
Omeros Corporation
Opium Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Lofexidine + Marinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vivitrol + Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylphenidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tramadol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methadone + Dextromethorphan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methadone + Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Opium Addiction Therapeutics - Discontinued Products
Opium Addiction - Featured News
Jul 07, 2010: Insight on MediciNova's MN-166 Mechanism of Action Reported in Proceedings of the National Academy of Sciences
Feb 18, 2010: Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference
Oct 29, 2007:
Oct 29, 2007: Celtic Pharma Completes rapid Enrollment In Phase IIB Study For TA-NIC (TANIC) The Nicotine Vaccine For Smoking Cessation
Apr 30, 2007: Celtic Pharma Receives IND Approval To Initiate A Large Randomized Study In The US For TA-NIC, Its Immunotherapy Vaccine For The Treatment Of Smoking Cessation
Jun 21, 2006: Celtic Pharma Reports Preliminary Results Of Phase II Clinical Trials With TA-CD, Cocaine Addiction Vaccine.
May 08, 2006: Celtic Pharma Announces Launch Of Phase II Clinical Trial For TANIC, A Vaccine Treatment For Nicotine Addiction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Opium Addiction, Q1 2011
Products under Development for Opium Addiction – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Pre-Clinical Stage Development, Q1 2011
Shionogi & Co., Ltd., 2011
Nanotherapeutics, Inc., 2011
AKELA Pharma Inc., 2011
MediciNova, Inc., 2011
Catalyst Pharmaceutical Partners, Inc., 2011
Orexo AB, 2011
Camurus AB, 2011
Omeros Corporation, 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Opium Addiction, Q1 2011
Products under Development for Opium Addiction – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos